PRDS changes CEO (to stop the bleeding): https://ir.pardesbio.com/news-releases/news-release-details/pardes-biosciences-appoints-thomas-g-wiggans-ceo-and-chairman The stock is down 63% from its high on 12/30/21, immediately after the closing of the SPAC merger. I last commented on PRDS in #msg-167908010.